Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: Identification of CJC-1295 as a long-lasting GRF analog

Endocrinology

Volumn 146, Issue 7, 2005, Pages 3052-3058

  Jetté, Lucie ^a   Léger, Roger ^a   Thibaudeau, Karen ^a   Benquet, Corinne ^a   Robitaille, Martin ^a   Pellerin, Isabelle ^a   Paradis, Véronique ^a   Van Wyk, Pieter ^a   Pham, Khan ^a   Bridon, Dominique P ^a  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN CONJUGATE; CJC 1295; GROWTH HORMONE RELEASING FACTOR DERIVATIVE; GROWTH HORMONE RELEASING FACTOR RECEPTOR; GROWTH HORMONE RELEASING FACTOR[1-29]; MALEIMIDE DERIVATIVE; SERUM ALBUMIN; UNCLASSIFIED DRUG; DIPEPTIDYL PEPTIDASE IV; DNA BINDING PROTEIN; DRUG DERIVATIVE; GROWTH HORMONE RELEASING FACTOR; PEPTIDE FRAGMENT; SERMORELIN; SOMATOTROPIN RELEASING HORMONE (1 29); SOMATOTROPIN RELEASING HORMONE (1-29); TRANSCRIPTION FACTOR;

ADENOHYPOPHYSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL CULTURE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG HALF LIFE; DRUG STABILITY; DRUG SYNTHESIS; EX VIVO STUDY; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; WESTERN BLOTTING; AMINO ACID SEQUENCE; ANIMAL; DRUG EFFECT; GENETICS; HALF LIFE TIME; HUMAN; METABOLISM; MOLECULAR GENETICS; SPRAGUE DAWLEY RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD26; CELLS, CULTURED; DNA-BINDING PROTEINS; DRUG STABILITY; GROWTH HORMONE-RELEASING HORMONE; HALF-LIFE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PITUITARY GLAND, ANTERIOR; RATS; RATS, SPRAGUE-DAWLEY; SERMORELIN; SERUM ALBUMIN; TRANSCRIPTION FACTORS;

EID: 22144468434     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2004-1286     Document Type: Article

References (34)

1. Giustina A, Veldhuis JD 1998 Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19:717-797
2. Frohman LA, Jansson JO 1986 Growth hormone-releasing hormone. Endocr Rev 7:223-253
3. Frohman LA, Downs TR, Williams TC, Heimer EP, Pan Y-CE, Felix AM 1986 Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J Clin Invest 78:906-913
4. D'Antonio M, Louveau I, Esposito P, Bertolino M, Canali S 2004 Pharmacodynamic evaluation of a PEGylated analogue of human growth hormone releasing factor in rats and pigs. Growth Horm IGF Res 14:226-234
5. Esposito P, Barbero L, Caccia P, Caliceti P, D'Antonio M, Piquet G, Veronese FM 2003 PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev 55:1279-1291
6. Vance ML, Kaiser DL, Evans WS, Furlanetto R, Vale W, Rivier J, Thorner MO 1985 Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). Evidence for intermittent somatostatin secretion. J Clin Invest 75:1584-1590
7. Warnecke A, Kratz F 2003 Maleimide-oligo(ethylene glycol) derivatives of camptothecin as albumin-binding prodrugs: synthesis and antitumor efficacy. Bioconjug Chem 14:377-387
8. Kratz F, Muller-Driver R, Hofmann I, Drevs J, Unger C 2000 A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. J Med Chem 43:1253-1256
9. Kratz F, Warnecke A, Scheuermann K, Stockmar C, Schwab J, Lazar P, Drückes P, Esser N, Drevs J, Rognan D, Bissantz C, Hinderling C, Folkers G, Fichtner I, Unger C 2002 Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin binding properties compared to that of the parent compound. J Med Chem 45:5523-5533
10. Kim J-G, Baggio LL, Bridon DP, Castaigne J-P, Robitaille MF, Jette L, Benquet C, Drucker DJ 2003 Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 52:751-759
11. Léger R, Thibaudeau K, Robitaille M, Quraishi O, van Wyk P, Bousquet-Gagnon N, Carette J, Castaigne J-P, Bridon DP 2004 Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog. Bioorg Med Chem Lett 14:4395-4398
12. Léger R, Benquet C, Huang X, Quraishi O, van Wyk P, Bridon D 2004 Kringle 5 peptide-albumin conjugates with anti-migratory activity. Bioorg Med Chem Lett 14:841-845
13. Léger R, Robitaille M, Quraishi O, Denholm E, Benquet C, Carette J, van Wyk P, Pellerin I, Bousquet-Gagnon N, Castaigne J-P, Bridon D 2003 Synthesis and in vitro analysis of atrial natriuretic peptide-albumin conjugates. Bioorg Med Chem Lett 13:3571-3575
14. Holmes DL, Thibaudeau K, L'Archêveque B, Milner PG, Ezrin AM, Bridon DP 2000 Site specific 1:1 opioid:albumin conjugate with in vitro activity and long in vivo duration. Bioconjug Chem 11:439-444
15. Baird A, Wehrenberg WB, Ling N 1986 Relative potencies of human, rat, bovine/caprine, porcine and ovine hypothalamic growth hormone-releasing factors to release growth hormone by the rat anterior pituitary in vitro. Neuroendocrinology 42:273-276
16. Cervini LA, Donaldson CJ, Koerber SC, Vale WW, Rivier JE 1998 Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies. J Med Chem 41:717-727
17. Su C-M, Jensen LR, Heimer EP, Felix AM, Pan Y-CE, Mowles TF 1991 In vitro stability of growth hormone releasing factor (GRF) analogs in porcine plasma. Horm Metab Res 23:15-21
18. Campbell RM, Stricker P, Miller R, Bongers J, Liu W, Lambros T, Ahmad M, Felix AM, Heimer EP 1994 Enhanced stability and potency of novel growth hormone-releasing factor (GRF) analogues derived from rodent and human GRF sequences. Peptides 15:489-495
19. Bongers J, Heimer EP, Lambros T, Pan Y-CE, Campbell RM, Felix AM 1992 Degradation of aspartic acid and asparagine residues in human growth hormone-releasing factor. Int J Pept Protein Res 39:364-374
20. Campbell RM, Bongers J, Felix AM 1995 Rational design, synthesis, and biological evaluation of novel growth hormone releasing factor analogues.Biopolymers 37:67-88
21. Wilfinger WW, Larsen WJ, Downs TR, Wilbur DL 1984 An in vitro model for studies of intercellular communication in cultured rat anterior pituitary cells. Tissue Cell 16:483-497
22. Aleppo G, Moskal 2nd SF, De Grandis PA, Kineman RD, Frohman LA 1997 Homologous down-regulation of growth hormone-releasing hormone receptor messenger ribonucleic acid levels. Endocrinology 138:1058-1065
23. Sugihara H, Emoto N, Tamura H, Kamegai J, Shibasaki T, Minami S, Wakabayashi I 1999 Effect of insulin-like growth factor-I on growth hormone-releasing factor receptor expression in primary rat anterior pituitary cell culture. Neurosci Lett 276:87-90
24. Rafferty B, Poole S, Clarke R, Schulster D 1985 Growth hormone-releasing factor analogue (hGRF1-29NH2): immunoreactive-GRF plasma levels after intravenous and subcutaneous administration. J Endocrinol 107:R5-R8
25. Laemmli UK 1970 Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685
26. Zhou XH, Dinh P 2005 Nonparametric confidence intervals for the one- and two-sample problems. Biostatistics 6:187-200
27. Peters Jr T 1995 All about albumin: biochemistry, genetics and medical applications. New York: Academic Press; 230-232
28. Turner JP, Tannenbaum GS 1995 In vivo evidence of a positive role for somatostatin to optimize pulsatile growth hormone secretion. Am J Physiol 269:E683-E690
29. Sugihara H, Minami S, Okada K, Kamegai J, Hasegawa O, Wakabayashi I 1993 Somatostatin reduces transcription of the growth hormone gene in rats. Endocrinology 132:1225-1229
30. Leung K, Rajkovic IA, Peters E, Markus I, Van Wyk JJ, Ho KK 1996 Insulin-like growth factor I and insulin down-regulate growth hormone (GH) receptors in rat osteoblasts: evidence for a peripheral feedback loop regulating GH action. Endocrinology 137:2694-2702
31. Vance ML, Kaiser DL, Martha Jr PM, Furlanetto R, Rivier J, Vale W, Thorner MO 1989 Lack of in vivo somatotroph desensitization or depletion after 14 days of continuous growth hormone (GH)-releasing hormone administration in normal men and a GH deficient boy. J Clin Endocrinol Metab 68:22-28
32. Kovács M, Halmos G, Groot K, Izdebski J, Schally AV 1996 Chronic administration of a new potent agonist of growth hormone-releasing hormone induces compensatory linear growth in growth hormone-deficient rats: mechanism of action. Neuroendocrinology 64:169-176
33. Kovács M, Fáncsik A, Mezö I, Teplán I, Flerkó B 1994 Effects of continuous and repetitive administration of a potent analog of GH-RH(1-30)NH2 on the GH release in rats. Neuroendocrinology 59:371-379
34. Dubreuil P, Brazeau P, Moreau S, Farmer C, Coy D, Abribat T 2001 The use of pigs as an animal model to evaluate the efficacy, potency and specificity of two growth hormone releasing factor analogues. Growth Horm IGF Res 11:173-186